Silymarin in Combination with Vitamin C, Vitamin E, Coenzyme Q10 and Selenomethionine to Improve Liver Enzymes and Blood Lipid Profile in NAFLD Patients
| Autor: | Michele Pironti, Orazio Grassi, Adriana Romano, Donatella Schiaroli, Antonio Di Nicola, Giuseppe Fabrizio Nocera, Annalisa Curcio, Simona Cuozzo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Medicine (General) silymarin Diet Reducing Ubiquinone medicine.medical_treatment Blood lipids vitamin C Ascorbic Acid vitamin E Gastroenterology digestive system Article chemistry.chemical_compound R5-920 Non-alcoholic Fatty Liver Disease Internal medicine coenzyme Q10 medicine Humans Obesity Coenzyme Q10 Vitamin C business.industry Vitamin E Fatty liver General Medicine medicine.disease Lipids digestive system diseases chemistry Tolerability Liver non-alcoholic fatty liver disease (NAFLD) selenomethionine Alkaline phosphatase Liver function business |
| Zdroj: | Medicina; Volume 56; Issue 10; Pages: 544 Medicina Medicina, Vol 56, Iss 544, p 544 (2020) Volume 56 Issue 10 |
| ISSN: | 1648-9144 |
| DOI: | 10.3390/medicina56100544 |
| Popis: | Background and Objectives: Non-Alcoholic Fatty Liver Disease (NAFLD) is an emerging cause of hepatopathy that is showing an increasing trend and where the recommendations of lifestyle modification are often not sufficient. The aim of this study is to evaluate the efficacy and tolerability profile of the association of silymarin, vitamin C, vitamin E, coenzyme Q10 and selenomethionine (Medronys epato® ) by analyzing liver enzymes, along with the lipidic profile, as markers of liver function, and ultrasound results in NAFLD patients. Materials and Methods: This study enrolled 81 patients with mild to severe NAFLD, divided into two groups: Group A (N = 41) received two capsules a day of silymarin, vitamin C, vitamin E, coenzyme Q10 and selenomethionine (Medronys epato® ), and Group B (N = 40) received only recommendations for lifestyle modification including hypocaloric diet, physical exercise and encouragement for weight loss. Patients have been evaluated at three timepoints: baseline (T0), after 45 days of treatment (T1) and after 90 days of treatment (T2), by collecting blood parameters of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT) and the lipid blood profile. Ultrasonographic results have been analyzed at T0 and T2, along with the tolerability profile and side effects, registered at time T2. Results: The administration of the association of silymarin, vitamin C, vitamin E, coenzyme Q10 and selenomethionine (Medronys epato® ) was effective since it showed a significant reduction of the evaluated parameters of ALT, AST, ALP and GGT, a significant improvement of lipid parameters, evaluated as markers of liver function, and improvements of ultrasonographic results. The use of this formulation at the dosage of two capsules a day has been well tolerated and no adverse events have been reported during study period of three months. Conclusions: The administration of the association of silymarin, vitamin C, vitamin E, coenzyme Q10 and selenomethionine (Medronys epato® ) was effective and well tolerated in the improvement of hepatic function of NAFLD patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|